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Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tis-
sue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of
900–1500μg/m2 every 3 weeks. Results. We observed one complete remission, 5 partial remissions, one minimal response, and 16
patients with a disease stabilization of 6 months or more. The objective response rate was 6.7% and the clinical beneﬁt rate at 3
and 6 months was 37.7% and 23.4%, respectively. Responses were noted in patients with lipo-, leiomyo-, osteo-, and myogenic
sarcoma, with a median duration of 9.85 months. Toxicity mainly involved an asymptomatic elevation of transaminases and neu-
tropenia. Estimated 1- and 2-year survival rates were 39.4% and 15.8%. Median overall survival was 8.25 months. Discussion. This
retrospective analysis conﬁrms that ET-743 induces objective responses and progression arrest in a clinically relevant proportion
of patients.
Copyright © 2006 G. Huygh et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Soft tissue sarcomas (STSs) represent a heterogeneous family
of malignancies of mesenchymal origin, accounting for ap-
proximately 1% of all cancers worldwide each year [1]. De-
spite adequate treatment and control of localized disease, ap-
proximately 40% to 50% will eventually develop local recur-
rence or metastastic disease [2–5]. Once the tumor has pro-
gressed beyond surgical resectability, the disease is nearly al-
ways incurable, with a median survival of at best 12 months
[6, 7]. With some exceptions for speciﬁc histopathologic STS
subtypes such as GIST, the treatment options in this clinical
setting are limited to a few cytotoxic agents like doxorubicin
and ifosfamide. Although combination chemotherapy fol-
lowed by metastasectomy may sometimes be curative, most
patients with metastatic bone sarcoma still succumb to their
disease as well. Therefore, new eﬀective drugs in the treat-
ment of STS and bone sarcoma are desperately needed.
Ecteinascidin 743 (ET-743; Yondelis) is a marine-derived
alkaloid isolated from the Caribbean tunicate Ecteinascidia
turbinata. It was chosen for further clinical development as
an antineoplastic agent because of its unique mechanism of
action, which is not yet fully understood, and its cytotoxic
potency in early preclinical studies [8]. ET-743 interacts with
DNA in a sequence-speciﬁc manner; it covalently binds a
guanineresidueintheDNAminorgroove,bendingtheDNA
helix towards the major groove [9, 10]. ET-743 inhibits gene
activation via a promoter-speciﬁc mechanism [11, 12]a n d
interacts with transcription-dependent nucleotide excision
repair, inducing lethal DNA strand breaks [13]. In addition
ET-743 blocks the cell cycle in the late S and G2 phases
[14, 15], aﬀects the organization and assembly of the micro-
tubulenetwork[16],andabrogatestranscriptionalactivation
of the MDR 1 gene, which is involved in the development
of drug resistance, while leaving constitutive gene expression
relatively unaﬀected [11].
Preclinical studies have shown activity of ET-743 in sev-
eral solid tumor cell lines and xenografts, including STSs,
and demonstrated little cross-resistance with several stan-
dard chemotherapeutic agents [14, 17–19]. In the phase I
clinical setting, tumor responses were observed in patients
with a wide variety of malignancies, including leiomyosar-
coma,liposarcoma,andosteosarcoma[20–24].Invitrostud-
ies revealed that cytotoxicity of ET-743 was inﬂuenced by the
administration schedule, with more activity with continuous
exposure [14, 20, 23]. Subsequently, phase I trials showed2 Sarcoma
that the administration of ET-743 in a 24-hour continuous
intravenous infusion (CIV), once every 3 weeks (q3w), was
better tolerated and had a higher duration of exposure com-
pared with the 1-hour q3w and the once daily for 5 days q3w
schedules [20, 24]. It also had a higher dose-intensity com-
pared with the 72-hour CIV q3w schedule [23]. The recom-
mended dose for phase II was 1500μg/m2 q3w, which was
used in subsequent trials.
The demonstration of several objective responses and
clinically relevant disease stabilizations among pretreated
STS and bone sarcoma patients, as well as the need for ef-
fective new therapy in this clinical setting, encouraged fur-
ther exploration of ET-743 in this patient population. We re-
port here a retrospective analysis of patients with advanced
and metastastic STS and bone sarcoma, treated with ET-743
in a single institution. These patients were treated either in
a EORTC phase II trial or in a compassionate use program
in our center. In contrast with phase II trial conducted by
EORTC, we also included patients with osteosarcoma.
PATIENTS AND METHODS
Patientpopulation
The present report considers two patient cohorts. Fifteen ad-
vanced, pretreated sarcoma patients were included in a phase
II trial between March 1999 and September 2000. Another
74 patients, who were not eligible for the ongoing phase II
trial because of histology or previous treatment or who were
referred to our institution after closure of the phase II trial,
were treated with ET-743 (supplied by PharmaMar, Madrid,
Spain) on a named-patient basis, compassionate use pro-
gram. This program as well as the phase II trial was ap-
proved by the ethics committee of the University Hospital
of Leuven. Patients could be included in this program upon
request of the treating physician after approval of the com-
pany.
All patients eligible for the phase II trial were required
to have histologically proven, unresectable advanced, or
metastastic sarcoma, excluding the following histological
subtypes: chondrosarcoma, neuroblastoma, osteosarcoma,
Ewing’s sarcoma, malignant mesothelioma, and embryonal
rhabdomyosarcoma. Patients with gastrointestinal stroma-
cell tumors (GIST) received ET-743 as ﬁrst-line treatment,
as Imatinib was not available at that time. The other pa-
tients were pretreated with one line of previous single agent
chemotherapy, which had to be discontinued for more than
4 weeks (adjuvant chemotherapy was not considered as ﬁrst
line, unless the patient progressed within six months follow-
ing adjuvant chemotherapy).
All patients were required to have at least one measur-
able lesion located in a nonirradiated area, with evidence
of progression within 6 weeks prior to treatment (osseous
lesions, pleural eﬀusions, and ascites were not considered
measurable). Other eligibility criteria included the follow-
ing: age ≥18 years, ECOG PS of <2, adequate bone mar-
row reserve (neutrophil count ≥ 2 × 10∗9/ l and platelet
count ≥ 100 × 10∗9/ l), normal renal and hepatic function
(serumcreatinine ≤120μmol/lorcalculatedcreatinineclear-
ance (Cockroft formula) ≥60ml/min, AST and ALT < 1.5 ×
ULN in case of no liver metastasis or < 2.5 × ULN in case
of liver metastasis, alkaline phosphatase ≤ULN, bilirubine
≤ULN, albumine ≥25g/l), no other severe medical illness,
no central nervous system (CNS) metastases, and no prior
or concurrent second primary malignant tumors (except ad-
equately treated in situ carcinoma of the cervix or basal cell
carcinoma). Fertile males and females were to use medi-
cally approved contraception, pregnant or lactating women
were excluded. Patients were excluded if regular follow-up
attendance was impractical. All patients were required to
have an indwelling central venous access device (eg, port-
a-cath) in place for drug administration. A signed written
informed consent was obtained from each patient before ac-
crual.
The same inclusion criteria applied to patients entered
onto the compassionate use program, with the exception of
the following conditions, which were accepted in the com-
passionate use program and not in the phase II trial: age <18
(with parental authorization), ECOG PS 2, decreased blood
cell count, decreased renal or hepatic function, CNS involve-
ment, and pretreatment with more than 1 single-agent or
combination therapy. All subtypes of sarcoma were allowed.
For patients with angiosarcoma, previous treatment with
taxanes was recommended and for patients with GIST pre-
treatment with imatinib.
We further categorized our population in terms of the
anthracycline resistance (deﬁned as progression occurring
while under the anthracycline-containing treatment, within
3 months of completing palliative treatment or within 6
months of completing adjuvant treatment), and bulky dis-
ease (deﬁned as the existence of at least one tumor mass with
adiameterofatleast10cm).ThephaseIIandcompassionate
use patients were pooled for the purpose of this retrospective
analysis.
Treatmentplan
The primary endpoint of our analysis was to determine the
response rate and duration of response to ET-743 in ad-
vanced STS and bone sarcoma patients. The secondary end-
point was to further characterize the toxicity proﬁle of ET-
743 in this patient population. We also report on the clin-
ically relevant time-related parameters such as progression-
free survival (PFS) and overall survival (OS), for the entire
population and the STS subgroup.
Prestudy assessments were to be performed within 14
days before initiating therapy, including the following: med-
ical history, physical examination, performance status, com-
plete diﬀerential blood cell counts and blood chemistry
(urea, creatinine, sodium, potassium, calcium, glucose, AST,
ALT, alkaline phosphatase, bilirubin, LDH, and albumine),
urinanalysis (dip stick), chest X-ray, and radiologic evalua-
tion of all measurable or assessable sites. Complete diﬀeren-
tial blood cell counts and liver function tests were repeated
weekly; AST and ALT were also measured on day 3 of each
cycle.G. Huygh et al 3
Physical examination, performance status, complete dif-
ferential blood cell counts, blood chemistry, and urinanal-
ysis, were performed before each cycle of therapy. Toxicity
was evaluated in each cycle and graded according to the Na-
tional Cancer Institute—Common Toxicity Criteria (NCI-
CTC), version 3.0. Tumor response was evaluated every 2 cy-
cles until disease progression according to the WHO criteria
in the phase II trial and RECIST criteria in the compassion-
ate use program. Patients in the phase II trial who achieved
completeorpartialresponsewerereevaluated4weekslaterto
conﬁrm the initial observation of response. Responses were
reviewed by independent experts in the phase II trial, not in
the compassionate use program.
ET-743 was supplied as a sterile lyophilized product in a
clear vial, containing 250μg of ET-743 with 250mg of man-
nitol, 34mg of monopotassium phosphate, and phosphoric
acid to ajust pH until 4.00. Each vial was reconstituted with
5mlofsterilewaterforinjection.Thereconstitutionsolution
was further diluted in the desired amount of normal saline
andadministeredintravenouslyviaacentralvenouscatheter,
without the use of an inline ﬁlter.
In the phase II trial, ET-743 was administered at a dose
of 1500μg/m2 as a 24-hour CIV, repeated every 3 weeks. In
the compassionate use program, the starting dose of ET-743
was reduced (900–1350μg/m2) in the following cases: insuf-
ﬁcient haematological reserve, alkaline phosphatase eleva-
tion, bilirubin elevation, creatinine elevation, performance
status 2, and heavily pretreated patients. If the reduced dose
was well tolerated, the following cycle could be given at a
higher dose level. Dexamethasone 4mg was given orally ev-
ery12hoursfromthedaybeforetheadministrationuntilday
2. Before the treatment, 20mg of dexamethasone and on-
dansetron 8mg were given intravenously. Other antiemetic
agents such as lorazepam or metoclopramide could be ad-
ministeredapproximately15minutestotwohoursbeforethe
ET-743 infusion.
The treatment was administered every 3 weeks unless
there was insuﬃcient haematological recovery (ANC < 2 ×
10∗9/ l,platelets< 100×10∗9/ l),unlesscreatinine,transam-
inases,andbilirubinwerenotyetreturnedtonormalorbase-
line values, or unless grade 4 nonhematological toxicity was
not yet recovered, in which case treatment was interrupted
for up to 2 weeks until recovery. Treatment delays for more
than 2 weeks led to withdrawal from the study. In the com-
passionate use program, a longer delay was allowed. Dose
adjustments were based on the most severe toxicity noted
in the previous cycle. The dose of ET-743 was reduced to
1200μg/m2 in the phase II trial or to a lower dose level in
thecompassionateuseprograminthefollowingcases:febrile
neutropenia, grade 4 neutropenia lasting more than 5 days,
grade 4 thrombocytopenia, any nonhematological grade 3
to 4 toxicity (except grade 3 to 4 elevated AST/ALT), and
≥grade 1 increase of bilirubin or alkaline phosphatase. If
during a subsequent cycle there was a further episode of tox-
icity requiring a new dose reduction, the dose was reduced
to 1000μg/m2 in study patients or a lower dose level in the
compassionate use patients. Prophylactic use of cytokines
(G-CSF) was allowed only in case of febrile neutropenia oc-
curring in the prior cycle of treatment and if the dose had
already been reduced. Treatment with ET-743 was continued
until disease progression, patients refusal or excessive toxic-
ity precluding further therapy, according to the responsible
physician.
Statisticalmethods
Descriptive statistics were used to characterize response and
toxicity rates. The response rate was estimated as the propor-
tion of patients who achieved a complete or partial response
among all patients who received at least one cycle of ET-743.
Two-stage conditional exact binomial 95% conﬁdence inter-
vals (CI) were used to describe the distribution of the re-
sponse rate. χ2 was used for comparison of toxicities between
the phase II trial and the CU group.
Overall survival (OS), time to disease progression (TTP),
and duration of response were estimated according to the
Kaplan-Meier product-limit method. TTP was deﬁned as the
time from initiation of therapy to the ﬁrst documentation of
disease progression. OS was deﬁned as the time between the
ﬁrst study treatment and death. Duration of response was
deﬁned as the time between the ﬁrst documentation of ob-
jective response and documentation of disease progression.
Duration of stable disease was measured from the start of the
treatment until criteria for progression were met.
RESULTS
Patientcharacteristics
Between March 1999 and September 2000, 15 patients (7
women, 8 men) were treated in the phase II trial. Seventy-
four patients (33 women, 41 men) were treated in the
compassionate use program between September 1999 and
September 2004. At the time of analysis, 9 patients were still
on treatment with ET-743. Patient characteristics are sum-
marized in Table 1. The median age was 51 years (range, 16
to 76 years). The majority of patients was in good general
condition (84 patients ECOG PS 0 or 1; 5 patients ECOG
PS 2). The most common tumor types were leiomyosar-
coma (29 patients; 33%; 4 of which were of uterine origin),
liposarcoma (16 patients; 18%), and osteosarcoma (14 pa-
tients; 16%) (Table 1). All patients had metastastic or locally
advanced disease with a median of 3 involved sites (range, 1
to 7 sites), the most common sites being lung or pleura (71%
of patients), soft tissue (36% of patients, including primary
site of disease), lymph nodes (31% of patients), liver (28%
of patients), and bone (22% of patients, including primary
site of disease). Twenty-nine % of patients had bulky disease.
The median time between sarcoma diagnosis and initiation
of treatment with ET-743 was 24.0 months (range, 0.6 to 300
months).
Thepatientshadreceivedamedianof2priorchemother-
apyregimens(range,0to6regimens;Table 2).Threepatients
received ET-743 as ﬁrst-line treatment: one patient with
a leiomyosarcoma, one with a liposarcoma, and one with
GIST. Most patients (93%) had been previously treated with4 Sarcoma
Table 1: Patient characteristics at baseline. PS: performance status;
ECOG: eastern cooperative oncology group; HG: high grade.
Group 1(a)
(n = 15)
Group 2(b)
(n = 74) All (n = 89)
Number of patients (%)
Age, years
< 40 3 (20) 20 (27) 23 (26)
40–60 4 (27) 38 (51) 42 (47)
> 60 8 (53) 18 (22) 24 (27)
Median 61 51 51
Range 21–76 16–74 16–76
Sex
Female 7 (47) 33 (45) 40 (45)
Male 8 (53) 41 (55) 49 (55)
PS (ECOG)
0 4 (27) 28 (38) 32 (36)
1 11 (73) 41 (55) 52 (58)
2 0( 0 ) 5( 7 ) 5( 6 )
Tumor histology
Leiomyosarcoma 5 (33) 24 (32) 29 (33)
Nonuterine 5 (33) 20 (27) 25 (28)
Uterine 0( 0 ) 4( 5 ) 4( 5 )
Liposarcoma 1 (7) 15 (20) 16 (18)
Osteosarcoma 0 (0) 14 (19) 14 (16)
Synovial sarcoma 4 (27) 3 (4) 7 (8)
HG sarcoma 3 (20) 3 (4) 6 (7)
Other 2 (13) 15 (20) 19 (21)
Grade
High 11 (73,3) 36 (48,6) 47 (52,8)
Intermediate 1 (6,7) 5 (6,7) 6 (6,7)
Low 0 (0) 3 (4,1) 3 (3,3)
Unknown 3 (20) 30 (40,5) 33 (37,1)
Bulky disease(c)
Yes 3 (20) 23 (31) 26 (29)
No 12 (80) 51 (69) 63 (71)
Number of sites involved
Median 23 3
Range 1–4 1–7 1–7
Disease localization
Lung or pleura 11 (73) 52 (70) 63 (71)
Soft tissue 5 (33) 27 (36) 32 (36)
Lymph node 7 (47) 21 (28) 28 (31)
Liver 3 (20) 22 (30) 25 (28)
Bone 4 (27) 16 (22) 20 (22)
Time since initial
diagnosis (months)
Median 14 24 24
Range 0.6–90 4–300 0.6–300
< 12 6 (40) 14 (19) 20 (22)
12–36 5 (33) 22 (30) 27 (30)
> 36 4 (27) 28 (38) 32 (36)
(a)Group 1: patients treated in the phase II trial.
(b)Group 2: patients treated in a compassionate use program.
(c)Existence of at least one tumor mass with a diameter of at least 10cm.
anthracyclines, of which 55% were clinically resistant and
77 % were subsequently treated with ifosfamide. Seventy-
Table 2: Prior treatment.
Type of treatment
Group 1
(n = 15)
Group 2
(n = 74) All
(n = 89)
Number of patients (%)
Number of prior
chemotherapy regimens
0 1 (7) 2 (3) 3 (3)
1 10 (67) 25 (34) 35 (39)
2 4 (27) 29 (39) 33 (37)
≥ 3 0 (0) 18 (24) 18 (20)
Median 12 2
Range 0–2 0–6 0–6
Prior chemotherapy
Anthracyclines 13 (87) 70 (95) 83 (93)
Ifosfamide 8 (53) 59 (80) 67 (75)
Anthracycline clinical
resistance(a)
Resistant 9 (60) 37 (50) 46 (52)
Sensitive 4 (27) 33 (45) 37 (41)
Never exposed 2 (13) 4 (5) 6 (7)
Prior radiotherapy
Yes 5 (33) 32 (43) 37 (42)
No 10 (67) 42 (57) 52 (58)
(a)Anthracycline resistance: progression occurring while under
anthracycline-containing treatment, within 3 months of completing
palliative treatment or within 6 months of completing adjuvant treatment
with anthracyclines.
four % of the patient population had received prior ifos-
famide therapy and 42% prior radiotherapy (Table 2).
Drugdelivery
A total of 430 cycles of ET-743 were administered at the
time of this analysis, with a median number of 2 cycles for
an individual patient, ranging from 1 to 31 cycles. Thirteen
cycles (3%) were dose reduced for the following reasons:
self-limited transaminitis (8 cycles), neutropenia (2 cycles),
thrombocytopenia (1 cycle), and combination of throm-
bocytopenia and neutropenia (2 cycles). The administra-
tion of 91 cycles (21%) was delayed because of neutrope-
nia (27 cycles); thrombocytopenia (10 cycles); combination
ofthrombocytopeniaandneutropenia(2cycles);self-limited
transaminitis (15 cycles); combination of transaminitis and
neutropenia (5 cycles); combination of transaminitis, neu-
tropenia, and thrombocytopenia (1 cycle); infection (2 cy-
cles); and nonmedical reasons, such as holiday or patients
request (29 cycles).
At the time of this analysis, 80 patients have discontin-
uedtreatment.Thereasonsfordiscontinuationincludeddis-
ease progression in 63 patients (70%), elective surgery in 5
patients (6%), patient withdrawal in 6 patients (7%), and
toxicity in 6 patients (7%): one long lasting thrombocy-
topenia grade 2, 1 methicilline resistant staphylococcus au-
reus (MRSA) sepsis, 1 pancytopenia complicated with a fatalG. Huygh et al 5
gastrointestinal hemorrhage, 1 septic shock, and 2 patients
with asthenia and anorexia grade 3. Twenty-four (27%) of
patients received 6 cycles or more of ET-743.
Efﬁcacy
The objective response rate is shown in Table 3.T u m o rr e -
sponse could not be evaluated in 7 patients due to early dis-
continuationofthetreatmentforthefollowingreasons:toxic
death (2), long lasting hematotoxicity (2), and withdrawal of
consent for further treatment (3).
Among the 89 patients who received at least one dose of
ET-743, 6 objective responses were seen including one com-
plete remission and 5 partial responses (objective response
rate 6.7%; 95% CI, 1.4% to 12.1%). The complete remission
was seen in a patient with a myxoid liposarcoma after 6 cy-
cles, lasting for 8.7 months at the moment of the analysis,
and the patient is still continuing treatment. The partial re-
sponses occurred in two patients with a leiomyosarcoma, of
which one was of uterine origine, in one patient with a myx-
oid liposarcoma, one patient with a HG osteosarcoma, and
one patient with a myogenic sarcoma. One patient (with a
myxoid liposarcoma) received ET-743 as ﬁrst-line treatment,
all other responding patients had received prior anthracy-
clines, of whom one was clinically resistant. Four of the re-
sponding pretreated patients also received prior treatment
with ifosfamide. Two patients who experienced partial re-
mission exhibited liver metastases and one patient bulky dis-
ease. Median duration of response was 9.85 months (range,
2 to 43.5 months). One minor response (40% tumor reduc-
tion) was observed in a patient with a synovial sarcoma,
lasting for 5.8 months. Responses were seen in lung, liver,
retroperitoneal, and abdominal localizations, as well as in
lymph nodes and soft tissue. The characteristics of respond-
ing patients are summarized in Table 4. Furthermore, 16 pa-
tients experienced disease stabilization for 6 months or more
(median8.75months;range,6.8to45months),ofwhichone
patient with an alveolar soft part sarcoma.
One patient with osteosarcoma and lung metastasis went
oﬀstudy3monthsafterachievingapartialremission,having
received 8 cycles of ET-743, for an attempt of salvage surgery,
which was not successful. She eventually progressed one year
after treatment discontinuation and was retreated with ET-
743,whichwasdiscontinuedafteranother9cyclesbecauseof
only stabilization of disease and fatigue. Disease progression
was noted 7 months after restarting treatment with ET-743,
2 months after discontinuation of ET-743. Two patients (one
alveolar soft part sarcoma and one leiomyosarcoma) contin-
ued treatment at disease progression, respectively, after 18
and 13 cycles, leading to a marked slowering of the growth
speed, which was documented by comparing CT scans un-
der treatment with ET-743 with those under previous treat-
ments. Both patients are still under treatment with ET-743
at the moment of the analysis and have received 31 and 27
cycles of ET-743, respectively.
For 9 patients with liver or lung metastasis, intraabdomi-
nal, or retroperitoneal localization of disease, the therapeutic
impact of ET-743 permitted salvage surgery attempts. Seven
Table 3: Best response. CR: complete remission; PR: partial remis-
sion;MR:minimalresponse;SD:stabledisease;PD:progressivedis-
ease; NE: not evaluated; ORR: overall response rate.
Response
Group 1
(n = 15)
Group 2
(n = 74) All
(n = 89)
Number of patients (%)
CR 0 (0) 1 (1) 1 (1)
PR 1 (7) 4 (5) 5 (6)
MR 1 (7) 0 (0) 1 (1)
SD ≥ 6m o n t h s 4 (27) 12 (16) 16 (18)
SD ≥ 2a n d< 6m o n t h s 1 (7) 15 (20) 16 (18)
PD 5 (33) 38 (51) 43 (48)
NE 3 (20) 4 (5) 7 (8)
ORR 6.7% 6.7% 6.7%
Clinical beneﬁt,
CR+PR+MR+SD
≥ 3m o n t h s 7 (53) 27 (36) 34 (38)
≥ 6m o n t h s 5 (33) 16 (23) 21 (23)
patients were rendered macroscopically tumor-free, of which
2underwentsurgeryafewdaysbeforetheendoftheanalysis,
the other 5 remained progression-free for 40, 36, 6, 6, and 1
months, respectively. One patient with a myogenic sarcoma
achieved a partial remission after 4 cycles of treatment. He
underwent a complete resection after 8 cycles, followed by
radiotherapy and 4 cycles of ET-743 in an adjuvant setting,
after which disease recurrence developed.
Time-related parameters were updated until September
30, 2004. With a median follow-up of 8.25 months (range,
0.5 to 59 months), 63 patients have progressed and 66 pa-
tients died. Median TTP and OS in all patients were 2.0
months (range, 0.5 to 45 months) and 8.2 months (range,
0.5 to 59 months), respectively (Figures 1 and 2). 37.7%
and 23.4% of the patients were progression-free at 3 and 6
months, and the OS rate at 1 and 2 years was 39.4% and
15.8%, respectively. For the STS subgroup, the median TTP
and OS were 2.0 months (range, 0.5 to 45 months) and 8.75
months (range, 0.5 to 59 months), respectively, the PFS at 3
and 6 months were 43.9% and 28.1%, with a 1- and 2-year
survival rate of 43.0% and 18.2%. The TTP and OS in the
STS population are shown in Kaplan-Meier plots in Figures
3 and 4,r e s p e c t i v e l y .
Safety
All patients were assessed for safety. Hematologic and non-
hematologic toxicities are listed in Tables 5 and 6.T h ep r e -
dominant hematologic toxicity was neutropenia, reaching
grade 3 to 4 in 26% and 12% of the patients, respectively.
Only 7 patients developed a febrile neutropenia episode with
need for hospitalization and intravenous antibiotic admin-
istration, with need for G-CSF administration in one pa-
tient. One patient died as a result of septic shock. Anemia
a n dt h r o m b o c y t o p e n i ar e a c h e dg r a d e3t o4i n7 %a n d1 8 %6 Sarcoma
Table 4: Characteristics of responding patients. CR: complete remission; PR: partial remission; MR: minor response; SD: stable disease;
M: male; F: female; LMS: leiomyosarcoma; S: sarcoma; GIST: gastrointestinal stromacell sarcoma; ASPS: alveolar soft part sarcoma; ST: soft
tissue; Abd: abdominal; L: lung/pleura; Li: liver; Ret: retroperitoneal; P: peritoneal; LN: lymph nodes; Th: thyroid; K: kidney; B: bone; br:
brain.
Best
response
Patients
number (%) Sex Age
(years) Histology Disease
sites
Number of
previous
lines
Anthracycline
resistance(a) Bulky(b)
Response
duration
(months)
CR 1 (1.1) M 57 Liposarcoma ST, Abd 1 N N 8.7+
PR 5 (5.6)
F 71 LMS L 1 Y N 43.5
F 61 Osteosarcoma L 2 N N 15
M 46 Myogenic Li, LN, ST 2 N N 11
F 38 LMS uterus Li, L, ST, P 1 Y N 7.3
M 41 Liposarcoma Ret, P 0 — Y 2.7+
MR 1 (1.1) F 76 Synovial S L 1 N N 5.8
SD ≥ 6months 16 (17.9)
F 37 GIST Abd 0 — N 43.5
F 56 LMS LN, ST, L, B 2 N Y 19.3+
M 35 LMS L 2 N N 12.5
M 61 LMS Li, B 1 Y N 11
M 76 LMS L, Li, ST, K 1 N Y 7
F 42 LMS L, Li, ST 1 N N 7
F6 0L M S u t e r u s S T 2 Y N 6 . 8
F 31 Liposarcoma Th, Abd 2 N Y 12.2
F 58 Liposarcoma Abd 1 Y Y 8.5+
M 58 Liposarcoma Abd 2 N Y 8
M 53 Liposarcoma Retr, K 3 N Y 8+
F 40 Synovial S LN, ST, Li, P 1 N N 7
M 21 Synovial S L, LN 1 Y N 6.8
M 46 Spindle cell S L, B, skin 2 Y N 17+
M 29 ASPS L 1 N N 13.5
F 3 Osteosarcoma B, ST, br 2 Y N 9
(a)Anthracycline resistance: progression occurring while under anthracycline-containing treatment, within 3 months of completing palliative treatment or
within 6 months of completing adjuvant treatment with anthracyclines.
(b)Bulky disease: existence of at least one tumor mass with a diameter of at least 10cm.
+: Patients still undergoing treatment with ET-743, disease progression not yet reached.
of patients, respectively. One patient experienced a gastroin-
testinal hemorrhage due to prolonged grade 4 thrombocy-
topenia. In 3 patients grade 2 thrombocytopenia lasted for
more than one month, leading to discontinuation of therapy
in one of them. Transfusion of packed red blood cells and
platelets was required in 9 and 5 patients, respectively, but
was possibly not systematically reported for the compassion-
ate use group.
An acute self-limiting transaminitis was frequently ob-
served, with 39% and 3% of patients developing grade 3
and 4 elevation of ALT and AST, respectively. AST and ALT
peaked 3 to 5 days after completing the ET-743 infusion, and
resolved in almost all cases before the start of the next cycle
(15 cycles delayed because of transaminitis). In one patient
it was associated with asthenia and emesis grade 3, mandat-
ing hospitalization and eventually discontinuation of ther-
apy. An elevation of bilirubin and/or alkaline phosphatase
was less frequent (resp, in 6% and 7% of patients, in only
one patient, bilirubin and alkaline phosphatase were both el-
evated), resulting in drug delay in these patients. Renal fail-
ure occurred in one patient, secondary to a gastrointestinal
bleeding.
Other toxicities experienced during treatment are listed
inTable 6.Fatiguewasacommonsideeﬀect,NCI-CTCgrade
2 and 3, respectively, in 35% and 13% of the patients. Nau-
sea and vomiting were mild to moderate (grade 2 and 3
in 24% and 4% of the patients, resp) with the routine use
of antiemetics. Other toxicities were rare, such as alopecia
(grade 1 and 2 both in one patient), mucositis (grade 1, 2,
and 3, resp, in 2, 3, and 1 patients) and diarrhea (grade 2 and
3 in, resp, 4 and 1 patients). Toxicities, hematologic as well
as nonhematologic, were less frequent in the patients treated
in compassionate use, reaching signiﬁcance for neutropenia,
anemia, transaminitis, anorexia, nausea, and vomiting. All
biochemical toxicities were reassessed by an independent ex-
pert. For nausea, vomiting, and anorexia, a possible report-
ing bias must be considered. The lower incidence of toxicity
may also be explained in part by the lower mean dose per cy-
cle in the population that was treated per compassionate use
protocol.G. Huygh et al 7
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Figure 1: Kaplan-Meier curve of time to progression for the entire
population.
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Figure 2: Kaplan-Meier curve of overall survival for the entire pop-
ulation.
Ten treatment-related serious adverse events occurred,
leading to death in two patients (both treated in the phase II
trial), consisting of 7 episodes of febrile neutropenia (com-
plicated with a brain abcess, MRSA sepsis, and a fatal septic
shock), 2 gastrointestinal hemorrhages due to grade 3 and 4
thrombocytopenia, leading to renal failure and death in one
patient,andemesisandastheniagrade3incombinationwith
transaminitis grade 3 in one patient.
DISCUSSION
The treatment of unresectable advanced or metastatic soft
tissue sarcoma (STSs) remains a challenge for medical oncol-
ogists. Doxorubicin and ifosfamide represent the two most
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Figure 3: Kaplan-Meier Curve of time to progression for the STS
subgroup.
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Figure 4: Kaplan-Meier Curve of overall survival for the STS sub-
group.
active conventional agents in the treatment of STSs, both
showing response rates of 20–30% in non-pretreated pa-
tients [2–4, 25, 26]. Doxorubicin remains the ﬁrst-line treat-
ment of choice, as a single agent or in combination with
ifosfamide. However, its use is precluded by the risk of car-
diotoxicity.Ifosfamideisthereforethetreatmentofchoicefor
patients who have received the maximum-tolerated cumu-
lative dose of anthracyclines or after treatment failure with
anthracyclines. Response rates of ifosfamide in second-line
treatment unfortunately are much lower, varying from 6%
to 16% [27, 28]. Dose intensiﬁcation and combination ther-
apy may increase the response rate, with respective response
rates reaching 39-40% [29–31] and 45% [32] in phase II tri-
als, but at the expense of a substantial increase of toxicity8 Sarcoma
Table 5:Hematologictoxicities(NCI-CTCgrade)percycleandperpatient.NCI-CTC:NationalCancerInstituteCommonToxicityCriteria;
Gr: grade; FN: febrile neutropenia; NS: not signiﬁcant.
Total
Neutropenia Thrombocytopenia FN Anemia
Gr 3 Gr 4 Gr 3 Gr 4 Gr 2 Gr 3-4
Number of patients (%)
Per cycle
Phase II 59 24 (40.7) 9 (15.3) 3 (5.1) 2 (3.4) 2 (3.4) 15 (25.4) 1 (1.7)
CU 372 20 (5.4) 8 (2.2) 10 (2.7) 3 (0.8) 5 (1.3) 33 (8.8) 5 (1.3)
Total 431 54 (12.5) 17 (3.9) 13 (3.0) 5 (1.2) 7 (1.6) 48 (11.1) 6 (1.4)
χ2, P value <. 0001 <. 0001 NS .08 NS .0002 NS
Per patient
Phase II 15 10 (66.7) 5 (33.3) 3 (20) 2 (13.3) 2 (13.3) 6 (40) 1 (6.7)
CU 74 11 (14.9) 6 (8.1) 8 (10.8) 3 (4.1) 5 (6.7) 18 (24.3) 5 (6.7)
Total 89 21 (23.6) 11 (12.3) 11 (12.3) 5 (5.6) 7 (7.9) 24 (26.9) 6 (6.7)
χ2, P value <. 0001 <. 0001 NS NS NS NS NS
Table 6: Nonhematologic toxicities (NCI-CTC grade) per cycle and per patient. NCI-CTC, National Cancer Institute Common Toxicity
Criteria; Gr, grade; NS, not signiﬁcant.
Transaminitis Bilirubin Nausea/vomiting Anorexia Asthenia
T o t a l G r3 G r4 G r2 - 3 G r2 G r3 G r2 G r3 G r2 G r3
Number of patients (%)
Per cycle
Phase II 59 19 (32.2) 0 (0) 0 (0) 15 (25.4) 2 (3.4) 8 (13.6) 5 (8.5) 6 (10.2) 4 (6.8)
CU 372 59 (15.9) 5 (1,4) 5 (1.4) 23 (6.2) 2 (0.5) 21 (5.6) 3 (0.8) 61 (16.4) 10 (2.7)
Total 431 78 (18.1) 5 (1.2) 5 (1.2) 38 (8.8) 4 (0.9) 29 (6.7) 8 (1.8) 67 (15.5) 14 (3.2)
χ2, P value .027 NS NS <. 0001 .051 NS .0001 NS NS
Per patient
Phase II 15 10 (66.7) 0 (0) 0 (0) 7 (46.7) 2 (13.3) 5 (33.3) 5 (33.3) 5 (33.3) 4 (26.7)
CU 74 25 (33.8) 5 (6.7) 5 (6,7) 14 (18.9) 2 (2.7) 14 (18.9) 3 (4.1) 29 (39.2) 8 (10.8)
Total 89 35 (39.3) 5 (5.6) 5 (5.6) 21 (23.6) 4 (4.5) 19 (21.3) 8 (8.9) 34 (38.2) 12 (13.5)
χ2, P value .02 NS NS .02 .07 NS .0006 NS NS
without impact on survival. In the palliative setting of STS,
these more aggressive approaches can therefore not be rec-
ommended [27, 33].
Currently, no reliable therapeutic options exist after fail-
ure of treatment with anthracyclines and ifosfamide. All
newlyavailablecytotoxicagentstestedinpretreatedandnon-
pretreated patients have shown disappointing results, with
the exception of speciﬁc tumor types such as GIST, for which
targeted therapies are available. This report demonstrates
that a new marine-derived cytotoxic agent, ET-743, is ac-
tive in a subset of previously treated patients with STS and
bone sarcoma, showing a response rate of 6.7%, with accept-
able toxicity. Our results are in concordance with prelimi-
nary results of phase I and II trials that demonstrated re-
sponse rates ranging from 4% to 13% [5, 21, 34–36]. The
median overall survival of 8.25 months is also comparable
with results from other phase II trials [5, 21, 34]. Responses
were seen in patients with bulky disease, anthracycline resis-
tance, and liver metastases, known to be an adverse prognos-
tic factor for response and survival [6, 7], and were observed
in multiple disease sites, including lung, liver, and soft tis-
sue.
Among the 89 patients, one complete remission and 5
partial responses (lasting for a median of 9.85 months) were
achieved. One further patient experienced a clinically rel-
evant minor response (40% tumor reduction), lasting for
5.8 months. Although numerically, the response rate is low
(6.7%), responses are durable, and 23.4% of patients with
proven disease progression at initiation of treatment with
ET-743 were progression-free at 6 months. As suggested ear-
lier, clinical beneﬁt (CR+PR+MR+SD) could be a clinically
more relevant indicator of activity in the palliative setting of
advanced STS and bone sarcoma [36]. Indeed, the EORTC
SoftTissueandBoneSarcomaGroup(STBSG)haspublished
datathatindicatethatthevariablespredictingsurvivaldonot
necessarily correlate with the ones that predict objective re-
sponse to therapy [6], consistent with the ﬁnding in a retro-
spective analysis of 1154 patients that progression-free sur-
vival at 3 and 6 months correlates with overall survival, even
in the absence of objective response [37].G. Huygh et al 9
The clinical beneﬁt of ET-743 in our patient cohort, al-
though not mentioned as a main endpoint of this analysis
at the time of its conception, was 37.7% at 3 months and
23.4% at 6 months for the entire population and 43.9% and
28.1%, respectively, for the STS subgroup. These results are
consistent with the results of a phase II trial conducted by
Yovine et al in 36 patients that demonstrated clinical bene-
ﬁt of 38.8% and 24.1% at 3 and 6 months, respectively [5].
Median TTP in the entire population and the STS subgroup
were 2.0 months (range, 0.5 to 45 months) (Figure 1).
Adultsofttissuesarcomas,oftenwithosteosarcoma,have
generally been grouped together in clinical trials because of
the rarity of the distinct histologic subtypes. However, im-
portant diﬀerences in response to therapy exist between his-
tologic subsets of STSs. In a multivariate analysis of prog-
nostic factors performed by the EORTC STBSG, liposarcoma
histology was found to be an independent prognostic fac-
tor of response to chemotherapy [6]. It should be mentioned
that 2 major responses observed in our patient cohort, 1 CR
and 1 PR, occurred in patients with liposarcoma, both of the
myxoid subtype. This represents a response rate of 12.5%
for the subset of 16 patients with a liposarcoma included in
this analysis. If we consider disease control, a clinical bene-
ﬁt of 62.5% at 3 months and 31.3% at 6 months was calcu-
lated for this histologic subtype. Garcia-Carbonero et al pos-
tulated that the particular sensitivity of the myxoid liposar-
comas may be the result of a molecular mechanism related
to the DNA minor groove-binding activity of ET-743 and its
interactionwithanaberranttranscriptional regulator,gener-
ated from a translocation between chromosomes 12 and 16,
present in this histologic subtype [33]. Worth mentioning is
that the patient with liposarcoma who experienced a partial
responsewastreatedupfrontwithET-743.Itwasalreadysug-
gested by a study presented at ASCO in 2000 that ET-743 in
ﬁrst-line treatment may have higher response rates, with a
reported response rate of 18% in that trial [38].
Interestingly, responses were not only seen in patients
with liposarcoma, but also in leiomyosarcomas, which have
been reported to be relatively chemotherapy-resistant, par-
ticularlythoseofvisceraloriginwithlivermetastasis[6].Two
patients with a leiomyosarcoma, of which one was of uterine
origin and the other displayed liver metastasis, developed a
partial response. A third patient with partial remission had
a myogenic sarcoma, possibly a leiomyosarcoma, or a my-
oﬁbroblastic sarcoma. One minor response and 4 long last-
ing stabilizationswereobservedinpatients withsynovialsar-
coma, leading to a clinical beneﬁt at 3 and 6 months of 50%
and 25%, respectively.
Ourobservationsofbestresponseinliposarcoma,leiom-
yosarcoma, and synovial sarcoma are consistent with prelim-
inary reports from phase II trials using ET-743 in this pa-
tient population [5, 21, 33, 34]. Most clinical trials excluded
patients with osteosarcoma, explaining the very limited ex-
perience with ET-743 in this patient population. For sev-
eral years, new chemotherapeutic single agents were tested in
this tumor type, with disappointing results [19]. Laverdiere
et al did demonstrate 3 minor responses among 24 patients
with osteosarcoma in a nonrandomized phase II trial with
ET-743 [39]. Ruiz-Casado and Delaloge reported partial re-
sponses in 2 of 17 patients and 2 of 3 patients with osteosar-
coma [21, 34]. In our patient population, one patient with
osteosarcoma and lung metastasis achieved a partial remis-
sion after 4 cycles of ET-743. After 8 cycles of ET-743, she
was referred to a surgeon for salvage surgery, which was
not successful. She eventually progressed 1 year after treat-
ment discontinuation and experienced disease stabilization
for another 7 months under retreatment with ET-743, after
which she decided to discontinue treatment because of fa-
tigue. These promising results certainly merit further atten-
tion.
Also surprising was the long lasting (13.5 months) dis-
ease stabilization in one patient with an adult soft part
sarcoma, a histologic subtype reported to be resistant to
chemotherapy [6], but which can be stable for a long time
without treatment. Even after disease progression, the con-
tinuation of ET-743, which was approved by the company,
clearly slowed down the growth of the tumor, which was as-
sessed by comparing CT scans under treatment with ET-743
with those under previous treatments.
T r e a t m e n tw i t hE T - 7 4 3w a so v e r a l lw e l lt o l e r a t e da n d
toxicities encountered in our patient population were mostly
manageable, as was documented by the fact that only 6 pa-
tients discontinued treatment because of treatment-related
toxicity. Neutropenia was the most frequently occurring se-
rious side eﬀect (grade 3 and 4 in 26% and 12% of pa-
tients,resp),complicatedbyfebrileneutropeniain7patients.
Thrombocytopenia was mild, leading to drug delay in 13 cy-
cles. A transient transaminitis, with 39% and 3% of patients
developing grade 3 and 4 elevation of ALT and AST, respec-
tively, led to dose reduction in 8 cycles and treatment delay
in 21 cycles, but never necessitated treatment discontinua-
tion. Other toxicities were mild and usually transient. The
low rate of alopecia (only in two patients) is of note. We ob-
served higher toxicity in the group of patients treated in the
phase II trial, in which two toxic deaths occurred: one gas-
trointestinal hemorrhage due to thrombocytopenia grade 4
and one neutropenic septic shock. The better tolerability in
the compassionate use group can be explained by starting
dose adjustments that were made according to pretreatment,
performance status, haematology, and liver and renal func-
tion, which were implemented after the identiﬁcation of bio-
chemical parameters predictive for the occurrence of severe
toxicities[40].Forthenon-biochemicalsideeﬀects,however,
diﬀerences between the 2 groups may be partly due to re-
portingbias.Therewasanequaltolerabilitybetweenpatients
who were highly pretreated and patients who received ET-
743 as ﬁrst-, second-, or third-line treatment. We conﬁrmed
hereby the observation of Yovine that even heavily pretreated
patients tolerate this regimen well when guidelines for pa-
tient selection and dose adjustments are respected [5].
In conclusion, this report shows that ET-743, in a 24-
hour CIV regimen, induces long lasting objective remissions
and tumour control in a clinically relevant proportion of
advanced sarcoma, resistant to or relapsed under conven-
tional therapies. Further evaluation of the activity of ET-743
in sarcomas is therefore warranted, not only after failure of10 Sarcoma
conventional chemotherapy, but also in earlier stages of the
disease and in combination regimens. The activity of ET-743
is not limited to STS, but is also seen in osteosarcoma. Fur-
therresearchonpredictivefactorsforresponsetoET-743will
be useful to better select which patients to treat with this new
drug.
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